Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Inclusion Criteria: * Patients diagnosed with histologically confirmed ovarian stromal tumor (granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor \[androblastoma\], steroid \[lipid\] cell tumor, gynandroblastoma, unclassified sex cord stromal tumor, sex cord tumor with annular tubules) * Patients must have recurrent stromal tumor having received no more than one prior chemotherapy regimen * Patients must have measurable disease as defined by Gynecological Oncology Group (GOG) Response Evaluation Criteria in Solid Tumors (RECIST) criteria * White blood count equal to or greater than 3000/mcl * Granulocyte count equal to or greater than 1500/mcl * Platelet count equal to or greater than 100,000/mcl * Creatinine equal to or less than 2.0 mg% * Bilirubin less than or equal to 1.5 times normal * Serum glutamic oxaloacetic transaminase (SGOT) less than or equal to 3 times normal * Patients with a GOG performance grade of 0, 1 or 2 * Patients of child bearing potential must have a negative pregnancy test and must agree to practice an effective means of birth control * Patients who have met the pre-entry requirements as specified * Patients must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization Exclusion Criteria: * Patients with GOG performance grade of 3 or 4 * Patients with a prior invasive malignancy (except non-melanoma skin cancer) who have had any evidence of disease within the last 5 years or whose prior malignancy treatment contraindicates the current protocol therapy * Patients having received more than one prior chemotherapy regimen * Patients amenable to cure by surgery * Patients with prior radiation except for those whose recurrent disease is outside the radiation port